Our analysis showed that combined treatment with BEZ235 and regorafenib enhanced the cellular toxicity, and inhibited cell migration and invasion in HCC cells via inhibition of the Akt/mTOR pathway. Here, MTOR is linked to hepatocellular carcinoma.